Molecular Templates, Inc. (MTEM): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTEM POWR Grades
- Sentiment is the dimension where MTEM ranks best; there it ranks ahead of 89.48% of US stocks.
- The strongest trend for MTEM is in Growth, which has been heading down over the past 81 days.
- MTEM ranks lowest in Momentum; there it ranks in the 7th percentile.
MTEM Stock Summary
- MTEM has a higher market value than only 10.34% of US stocks; more precisely, its current market capitalization is $33,529,230.
- The capital turnover (annual revenue relative to shareholder's equity) for MTEM is 8.46 -- better than 95.84% of US stocks.
- In terms of volatility of its share price, MTEM is more volatile than 96.57% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to MOLECULAR TEMPLATES INC, a group of peers worth examining would be SELB, RXDX, PLRX, RAPT, and TSVT.
- Visit MTEM's SEC page to see the company's official filings. To visit the company's web site, go to www.mtem.com.
MTEM Valuation Summary
- In comparison to the median Healthcare stock, MTEM's price/sales ratio is 55% lower, now standing at 0.9.
- Over the past 217 months, MTEM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for MTEM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MTEM | 2022-11-25 | 0.9 | 8.0 | -0.4 | -0.8 |
| MTEM | 2022-11-23 | 1.0 | 8.2 | -0.4 | -0.8 |
| MTEM | 2022-11-22 | 1.0 | 8.5 | -0.4 | -0.8 |
| MTEM | 2022-11-21 | 0.9 | 7.7 | -0.4 | -0.8 |
| MTEM | 2022-11-18 | 1.0 | 8.1 | -0.4 | -0.8 |
| MTEM | 2022-11-17 | 0.9 | 7.7 | -0.4 | -0.8 |
MTEM Growth Metrics
- Its 3 year cash and equivalents growth rate is now at -48.3%.
- Its 4 year net cashflow from operations growth rate is now at -29.16%.
- Its 3 year net cashflow from operations growth rate is now at -1453.07%.
The table below shows MTEM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 35.107 | -93.053 | -80.912 |
| 2022-06-30 | 33.246 | -93.436 | -86.661 |
| 2022-03-31 | 43.963 | -100.297 | -77.842 |
| 2021-12-31 | 38.697 | -30.387 | -83.009 |
| 2021-09-30 | 24.23 | -29.432 | -101.211 |
| 2021-06-30 | 26.149 | -24.44 | -94.049 |
MTEM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MTEM has a Quality Grade of C, ranking ahead of 37.75% of graded US stocks.
- MTEM's asset turnover comes in at 0.13 -- ranking 237th of 681 Pharmaceutical Products stocks.
- AGEN, ARDX, and LGND are the stocks whose asset turnover ratios are most correlated with MTEM.
The table below shows MTEM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.130 | 1 | -0.688 |
| 2021-03-31 | 0.102 | 1 | -1.004 |
| 2020-12-31 | 0.123 | 1 | -0.976 |
| 2020-09-30 | 0.133 | 1 | -0.940 |
| 2020-06-30 | 0.146 | 1 | -1.283 |
| 2020-03-31 | 0.139 | 1 | -1.005 |
MTEM Price Target
For more insight on analysts targets of MTEM, see our MTEM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.43 | Average Broker Recommendation | 1.33 (Strong Buy) |
MTEM Stock Price Chart Interactive Chart >
MTEM Price/Volume Stats
| Current price | $0.51 | 52-week high | $4.45 |
| Prev. close | $0.54 | 52-week low | $0.48 |
| Day low | $0.50 | Volume | 271,262 |
| Day high | $0.54 | Avg. volume | 201,480 |
| 50-day MA | $0.63 | Dividend yield | N/A |
| 200-day MA | $1.27 | Market Cap | 28.65M |
Molecular Templates, Inc. (MTEM) Company Bio
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.
Latest MTEM News From Around the Web
Below are the latest news stories about MOLECULAR TEMPLATES INC that investors may wish to consider to help them evaluate MTEM as an investment opportunity.
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare ConferenceAUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside |
Molecular Templates Third Quarter 2022 Earnings: Beats ExpectationsMolecular Templates ( NASDAQ:MTEM ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.24m (up 78% from 3Q... |
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue EstimatesMolecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Molecular Templates, Inc. Reports Third Quarter 2022 Financial ResultsAUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases, today reported financial results and business updates for the third quarter of 2022. “We are ex |
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual MeetingAUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will |
MTEM Price Returns
| 1-mo | -13.01% |
| 3-mo | -27.71% |
| 6-mo | -47.57% |
| 1-year | -88.36% |
| 3-year | -95.72% |
| 5-year | -93.80% |
| YTD | -86.99% |
| 2021 | -58.25% |
| 2020 | -32.86% |
| 2019 | 246.16% |
| 2018 | -59.68% |
| 2017 | 107.02% |
Continue Researching MTEM
Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...